Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump's new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

| More on:
A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

US President Donald Trump has signed an executive order aimed at reducing drug costs for Americans, by up to 80% immediately.

The move immediately hit Australia's pharmaceutical industry as 3 ASX pharmaceutical stocks crashed up to 10% shortly after the announcement.

Telix Pharmaceuticals Ltd (ASX: TLX) shares dropped 8.7% on Monday, to $24.47. The stock price has since recovered some losses, increasing 3.6% to $25.36 and has continued an upward trajectory today. It still has some way to go before it reaches the $29-mark seen earlier this month.

Similarly, Neuren Pharmaceuticals Ltd (ASX: NEU) shares dropped 9.56% at the close on Monday, to $12.02. The company share price has recovered some losses over the past 24 hours, rising 2.6% at the close yesterday. There are indications of another small increase today.

Clarity Pharmaceuticals Ltd (ASX: CU6) also followed the same trend. Its shares dropped 8.64% on Monday to $2.22 before rising 15.3% yesterday. The pharmaceuticals stock has experienced a steady decline since October last year before bottoming out in April.

What is Trump's executive order, and why is it affecting ASX pharmaceutical stocks?

As news.com reported:

What that means, in essence, is the US government will buy drugs at the lowest price they're being purchased for in other countries…Mr Trump is of the opinion that this will lead to lower prices in the United States, and that pharmaceutical companies will compensate by charging the rest of the world more.

The order, which has been described as a "game changer", casued an immediate drop of share prices for 3 ASX pharmaceutical stocks following fears that they will be forced to lower their drug prices. 

"Starting today, the United States will no longer subsidise the health care of foreign countries, which is what we were doing, we're subsidising others' health care, in countries where they pay a small fraction of what, for the same drug, that what we pay," US President Trump told reporters Monday at the White House. 

He said that big pharmaceutical companies will either have to abide by his new principle voluntarily. If not, he'll use the power of the federal government to ensure "we are paying the same price of other countries". 

The President tried to implement something similar during his first term in office, but was prevented by the courts. He slammed the idea as ineffective when Kamala Harris suggested it during last year's election campaign. Now he appears to have recommitted to the policy.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

woman in lab coat conducting testing representing biotech
Healthcare Shares

Is this soaring ASX 200 healthcare share just getting started?

If its lead therapy gets US approval, the stock can continue to climb.

Read more »

A happy elderly woman smiles and cheers as she looks at good investment news on her laptop.
Broker Notes

Macquarie forecasts this $3.4 billon ASX healthcare share is set surge 33%

Macquarie tips material outperformance from this ASX healthcare share in 2026.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Own CSL shares? Here are the key dates for 2026

It's been a bad year for CSL shares. What's ahead in 2026?

Read more »

A graphic of a pink rocket taking off above an increasing chart.
Healthcare Shares

Guess which ASX 300 healthcare share is rocketing 28% on global expansion news

Investors are piling into the ASX 300 healthcare share on Tuesday. Let’s see why.

Read more »

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
Healthcare Shares

Is Sigma Healthcare share a healthy buy, after hitting new lows?

The Chemist Warehouse merger and ageing population might boost this stock's appeal.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Telix shares fall despite 'significant milestone'

Let's see what the biotech has announced on Monday.

Read more »

A male doctor wearing a white doctor's coat shrugs and holds his hands up to indicate the unimpressive CSL share price as a result of OOVID-19
Healthcare Shares

Here's the earnings forecast out to 2030 for CSL shares

How healthy will the profit growth be in the coming years?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Up 680% since July, here's why 2025 was a breakout year for this hot ASX stock

With consistent contract wins, FDA clearance, and backing from Pro Medicus, 4D Medical is showing that there is a commercial…

Read more »